We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Global Blood Glucose Monitoring Devices Market to Reach USD 13 Billion by 2023

By LabMedica International staff writers
Posted on 16 Mar 2020
Print article
Illustration
Illustration
The global blood glucose monitoring devices (BGMDs) market was valued at nearly USD 8 billion in 2018 and is projected to grow at a fast-paced CAGR of approximately 11% to reach USD 13 billion by 2023, driven by the phenomenal sales growth of new revolutionary continuous glucose monitoring systems (CGMs). However, the growth of CGMs will be offset by a steady decline in the blood glucose meters (BGMs) segment due to continued extreme price competition/downward pricing pressure, lowered test-strip reimbursement, and market saturation of lower-cost meters, among other factors.

These are the latest findings of Research and Markets (Dublin, Ireland), a leading market research store.

The overall BGMDs market is being driven by several positive factors, including a strong demand for discreet, accurate CGM devices that provide convenient blood glucose monitoring 24/7 and eliminate frequent/cumbersome and painful fingersticks; steadily increasing awareness and adoption of new, next-generation CGMs on the back of strong sales/marketing/advertising and physician referrals; solid clinical outcomes due to the ability to improve the accuracy of insulin delivery and improve glycemic control or time-in-range (TIR) via continuous (24/7) glucose monitoring; the ability to integrate lucrative CGM sensors into fast-growing next-generation hybrid closed-loop insulin pump systems, better patient awareness and physician understanding of glucose trends and impact of diet/medication/exercise/lifestyle factors due to the use of smartphone-driven digital health coaching apps, resulting in improved diabetes management; ability to lower overall healthcare costs; solid reimbursement; low CGM market penetration (due to newness of technology), leaving much room for market growth in a large and expanding diabetes population; and sales of lucrative recurring CGM disposables (sensors) and accessories.

Related Links:
Research and Markets


Print article

Channels

Molecular Diagnostics

view channel
Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)

Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children

MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria. MiRNAs comprise a class of about 20 n... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.